158 related articles for article (PubMed ID: 23638223)
1. Overexpression of IL-9 receptor in diffuse large B-cell lymphoma.
Lv X; Feng L; Fang X; Jiang Y; Wang X
Int J Clin Exp Pathol; 2013; 6(5):911-6. PubMed ID: 23638223
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
Lv X; Feng L; Ge X; Lu K; Wang X
J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin D (IgD) and IgD receptor expression in diffuse large B-cell lymphoma.
Dai X; Wu YJ; Jia XY; Chang Y; Wu HX; Wang C; Wei W
Hematology; 2019 Dec; 24(1):544-551. PubMed ID: 31315540
[No Abstract] [Full Text] [Related]
4. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
5. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(5):3498-503. PubMed ID: 22528513
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL).
Markovic O; Marisavljevic D; Cemerikic-Martinovic V; Martinovic T; Filipovic B; Stanisavljevic D; Zivković R; Hajder J; Stanisavljevic N; Mihaljevic B
Med Oncol; 2012 Dec; 29(5):3515-21. PubMed ID: 22528517
[TBL] [Abstract][Full Text] [Related]
7. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.
Ohshima K; Kawasaki C; Muta H; Muta K; Deyev V; Haraoka S; Suzumiya J; Podack ER; Kikuchi M
Histopathology; 2001 Aug; 39(2):156-62. PubMed ID: 11493332
[TBL] [Abstract][Full Text] [Related]
8. MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma.
Ye H; Lu L; Ge B; Gao S; Ma Y; Liang B; Yu K; Yang K
Int J Clin Exp Pathol; 2015; 8(10):13043-50. PubMed ID: 26722499
[TBL] [Abstract][Full Text] [Related]
9. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
Loo SK; Ch'ng ES; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
Histopathology; 2017 Jul; 71(1):98-111. PubMed ID: 28248435
[TBL] [Abstract][Full Text] [Related]
10. High expression and nuclear localization of β-catenin in diffuse large B-cell lymphoma.
Ge X; Lv X; Feng L; Liu X; Wang X
Mol Med Rep; 2012 Jun; 5(6):1433-7. PubMed ID: 22427053
[TBL] [Abstract][Full Text] [Related]
11. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
Yao XX; Wang JF; Wang YH; Gao N
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
[TBL] [Abstract][Full Text] [Related]
12. High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome.
Li HJ; Sun QM; Liu LZ; Zhang J; Huang J; Wang CH; Ding R; Song K; Tong Z
Oncol Rep; 2015 Aug; 34(2):795-802. PubMed ID: 26082242
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
14. A Preliminary Study on Metadherin as a Potential Marker for Progression of Diffuse Large B Cell Lymphoma.
Ge X; Sui X; Fang X; Jiang Y; Ding M; Liu X; Wang X
Genet Test Mol Biomarkers; 2018 Aug; 22(8):481-486. PubMed ID: 30117777
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of regulatory B-cell markers, transforming growth factor β and interleukin-10 as a prognostic factor in diffuse large B-cell lymphoma.
Mishina T; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yamada K; Moritsubo M; Inoue-Mitsuyama K; Shimasaki Y; Imamoto T; Kawamoto K; Furuta T; Kohno K; Kato K; Akashi K; Ohshima K
Pathol Res Pract; 2024 Feb; 254():155117. PubMed ID: 38262270
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
17. Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma.
Chen F; Liu S; Zhou Y; Shen H; Zuo X
Hematology; 2016 Aug; 21(7):399-403. PubMed ID: 27077767
[TBL] [Abstract][Full Text] [Related]
18. BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas.
Takahata H; Ohara N; Ichimura K; Tanaka T; Sato Y; Morito T; Takata K; Kojima M; Kobata T; Yoshino T
J Clin Exp Hematop; 2010; 50(2):121-7. PubMed ID: 21123970
[TBL] [Abstract][Full Text] [Related]
19. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
20. Serum IL-6, IL-8, IL-10 and beta2-microglobulin in association with International Prognostic Index in diffuse large B cell lymphoma.
Duletić-Nacinović A; Stifter S; Marijić B; Lucin K; Valković T; Petranović D; Jonjić N
Tumori; 2008; 94(4):511-7. PubMed ID: 18822687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
